Algorithm Life In Focus    
-  +
  • Plant established in Lebanon as "CHARLES. E. FROSST & CO. (M.E.) S.A.L". It was initially built in 1962 and later expanded in 1974. It has operated as a subsidiary of MERCK & CO. INC. (MSD) until December 1989
  • Ownership transferred to a group of Lebanese nationals, shareholders of Drogureie de L'Union - distributors of MSD in Lebanon. The company name was changed to ALGORITHM SAL.
    All manufactured products were still under license from MSD
  • Agreement with Recordati to manufacture and promote its products in the Middle East, namely Lercadip, Lomexin and Urispas
  • Strategic alliance with Biogen to market Avonex (betaferon) in the MENA region. Avonex being a biotech product indicated for multiple sclerosis
  • Launch of Lercadip (lercanidipine); the first 3rd generation lipophilic Calcium Antagonist Dihydropiridine indicated for Hypertension.
  • Launch of the first one shot gynecological antifungal treatment, Lomexin (fenticonazole).
  • Launch of Urispas (flavoxate) creating the untapped market of urge incontinence
  • Launch of the first generic: Captace (captopril) enhancing the presence of Algorithm in the cardiovascular field
  • Partnership with Eli Lilly focusing on the Lebanese market
  • Regional service agreement with Biologix FZCo (based in Dubai, UAE) for the promotion of biotech products
  • Expansion of the regional biotech business to promote products of Astellas and Cephalon
  • Further expansion with new regional agreements with Shire, Tercica and Celgene
  • Global acquisition of Aggrastat (tirofiban) by Iroko Cardio LLC from Merck & Co. Marketing in the Middle East granted to Algorithm.
  • Expansion of the partnership with Lilly to include promotion of products in the Gulf: Glustin, Prozac and Evista
  • Regional agreement with Ipsen to promote its portfolio in most markets of the area
  • Launch of Silosin (silodosin, under license from Recordati & Kissei) indicated for BPH. The launch in Lebanon was the 3rd one worldwide after the launches in Japan and USA
  • Launch of Zanipress, the only antihypertensive with a fixed combination of a Dihydropiridine Calcium Antagonist (lercanidipine) and an ACE Inhibitor (enalapril), also under license form Recordati
  • Launch of Livazo (pitavastatin) under-license from Kowa. Livazo is the only potent statin uniquely combining effective control on LDL-C & TG, unique long-term incremental HDL-C increase and superior safety profile
  • Launch of Adenuric (febuxostat) in Lebanon under-license from Teijin. Adenuric is a breakthrough in the management of gout.
  • Launch of Livazo (pitavastatin) in Jordan under-license from Kowa, a novel efficacious and differentiated statin.
  • Algorithm acquired from Ipsen the secondary packaging and marketing authorization for Smecta / Smectalia (diosmectite). Smectalia is the first line treatment of acute and chronic diarrhea for children and adults.
  • Launch of Livazo (pitavastatin) in Kuwait and UAE.
  • Launch of Zorvolex (diclofenac) the first and only FDA-approved low dose NSAID developed using proprietary SoluMatrix Fine Particle Technology™.
  • Launch of Livazo (pitavastatin) in Saudi Arabia.
  • Launch of Adenuric (febuxostat) in Kuwait.